Metabolic Neuropathy Medication
- Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE more...
See Medical Care for a full discussion of recent and ongoing studies and symptomatic treatment.
These agents increase peristalsis of upper GI tract.
Sensitizes tissue to action of acetylcholine and stimulates motility of upper GI tract; indicated for gastroparesis. In severe gastroparesis, is not absorbed and should be given IV.
Therapy must be comprehensive and cover all likely pathogens in the context of neuropathic enteropathy.
Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication orally.
Treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s).
Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis).
These agents increase peristalsis and secretions in the intestine. They also increase contraction and relaxation of the sphincter of the bladder. They may help in treatment of cystopathy.
Used for selective stimulation of bladder to produce contraction to initiate micturition and empty bladder. Most useful in patients who have bladder hypocontractility, provided they have functional and coordinated sphincters. Rarely used because of difficulty in timing effect and because of GI stimulation.
These agents have been shown to be effective in treating painful diabetic neuropathy. They act on CNS, preventing reuptake of norepinephrine and serotonin at synapses involved in pain inhibition. Benefits are unrelated to relief of depression.
Analgesic for certain types of chronic and neuropathic pain.
Has demonstrated effectiveness in treatment of chronic pain. By inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, this drug increases synaptic concentration of these neurotransmitters in CNS.
Pharmacodynamic effects such as desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play roles in its mechanisms of action.
Selective serotonin reuptake inhibitors
These agents specifically inhibit presynaptic reuptake of serotonin but not noradrenaline.
Effective in painful diabetic neuropathy.
Use of certain anti-epileptic drugs, such as the GABA analogue gabapentin, has proven helpful in some cases of neuropathic pain. Thus, a trial of such an agent might provide analgesia for symptomatic neuropathy.
Blocks sodium channels nonspecifically and therefore reduces neuronal excitability in sensitized C-nociceptors. Has been demonstrated effective in neuropathic pain but suppresses insulin secretion and may precipitate hyperosmolar coma in patients with diabetes.
Nonspecific sodium channel blocker that has been effective in treatment of painful diabetic neuropathy; more useful in trigeminal neuralgia.
Novel anticonvulsant with unknown mechanism of action; believed to antagonize glutamate excitotoxicity. Has demonstrated effectiveness in neuropathic pain, but doses in clinical trials were as high as 3600 mg.
Recent studies have demonstrated efficacy in different types of neuropathic pain.
Analgesic probably acting over both monoaminergic and opioid mechanisms. Monoaminergic effect shared with TCAs. Tolerance and dependence appear to be uncommon.
In order for a dopamine agonist to offer clinical benefit, it must stimulate D2 receptors. The role of other dopamine receptor subtypes is currently unclear. They inhibit noxious input to spinal cord.
Has actions over noradrenergic receptors.
Studies have demonstrated efficacy in different types of neuropathic pain. Capsaicin has been shown to have efficacy in treatment of painful diabetic neuropathy and postherpetic neuralgia.
Derived from chili peppers; depletes substance P from sensory nerves, causing chemodenervation. Has demonstrated effectiveness in several studies of diabetic neuropathic pain and in other types of neuropathic pain.
Selective serotonin and norepinephrine reuptake inhibitors (SSNRI)
SSNRIs have antidepressant and central pain inhibitory actions.
The efficacy of duloxetine in the treatment of neuropathic pain associated with diabetic peripheral neuropathy was established in 2 large, randomized, placebo-controlled trials in adult patients. These studies led to duloxetine becoming the first FDA-approved agent for the treatment of diabetic neuropathic pain. Action is believed to involve inhibition of central pain mechanisms at the recommended dose of 60 mg/d PO.
Tamborlane WV, Ahern J. Implications and results of the Diabetes Control and Complications Trial. Pediatr Clin North Am. 1997 Apr. 44(2):285-300. [Medline].
Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010 Aug. 10(4):276-82. [Medline].
Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. 1999 Aug 30. 107(2B):2S-8S. [Medline].
Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. 2011 May-Jun. 25(3):159-67. [Medline].
Stirban A. Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep. 2014 Nov. 14(11):541. [Medline].
Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999 Dec 10. 53(9):2113-21. [Medline].
Harati Y. Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin. 1992 Aug. 10(3):783-807. [Medline].
Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab. 1977 Dec. 3(4):245-56. [Medline].
Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):9S-16S. [Medline].
Chalk CH. Acquired peripheral neuropathy. Neurol Clin. 1997 Aug. 15(3):501-28. [Medline].
Dick PJ, Thomas PK, eds. Peripheral Neuropathy. 3rd ed. Philadelphia: WB Saunders Co; 1993.
Comi G, Corbo M. Metabolic neuropathies. Curr Opin Neurol. 1998 Oct. 11(5):523-9. [Medline].
Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. Dick PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: WB Saunders Co; 1993. 1221.
Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):34S-42S. [Medline].
Misiunas A, Niepomniszcze H, Ravera B, et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid. 1995 Aug. 5(4):283-6. [Medline].
Kyle RA. Monoclonal proteins in neuropathy. Neurol Clin. 1992 Aug. 10(3):713-34. [Medline].
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9. 354(10):1021-30. [Medline].
Simmons DN, Lisle DA, Linklater JM. Imaging of Peripheral Nerve Lesions in the Lower Limb. Techniques in Foot & Ankle Surgery. 2008/12. 7(4):224-237.
Lisle DA, Johnstone SA. Usefulness of muscle denervation as an MRI sign of peripheral nerve pathology. Australas Radiol. 2007 Dec. 51(6):516-26. [Medline].
Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry. 1998 Dec. 65(6):810-21. [Medline].
Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. 2008 Mar. 13(1):7-26. [Medline].
Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999 Dec. 83(3):389-400. [Medline].
Lagueny A. [Metabolic and nutritional neuropathies]. Rev Prat. 2000 Apr 1. 50(7):731-5. [Medline].
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008 Jul. 31(7):1448-54. [Medline]. [Full Text].
Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg. 1999 Dec. 189(6):584-93. [Medline].
Kaminski HJ, Ruff RL. Neurologic complications of endocrine diseases. Neurol Clin. 1989 Aug. 7(3):489-508. [Medline].
Kluding PM, Pasnoor M, Singh R, D'Silva LJ, Yoo M, Billinger SA, et al. Safety of Aerobic Exercise in People With Diabetic Peripheral Neuropathy. Phys Ther. 2014 Oct 2. [Medline].
Parry GJ. Management of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):27S-33S. [Medline].
|Small-Fiber Sensory||Large-Fiber Sensory||Autonomic|
|Burning pain||Loss of vibration||Heart rate changes|
|Cutaneous allodynia||Proprioception loss||Postural blood pressure change|
|Paresthesias||Loss of reflexes||Abnormal sweating|
|Lancinating pain||Slowed NCVs||Gastroparesis|
|Loss pain/temperature||Sensory ataxia||Impotence|
|Foot ulcers||Weakness||Abnormal ejaculation|
|Visceral pain loss|
|* Modified from Apfel, 1999.|